The first randomized clinical trial of psilocybin for cocaine use disorder has reported higher abstinence rates and a lower risk of relapse among participants who received psilocybin with psychotherapy.
The findings are encouraging.
They do not establish psilocybin as an approved or proven treatment for cocaine addiction.
Published in JAMA Network Open, the study included 40 adults who wanted to stop using cocaine. Half received a single dose of psilocybin alongside manualized psychotherapy. The other half received an active placebo with the same psychotherapy protocol.
During the 180 days after treatment, participants who received psilocybin reported more cocaine-abstinent days, were more likely to achieve complete abstinence, and experienced a longer time before their first lapse.
Six of the 20 participants in the psilocybin group reported complete abstinence through the end of follow-up. None of the 20 participants assigned to the active-placebo group achieved that outcome.
The psilocybin group also had a 72 percent lower estimated risk of cocaine lapse over time.
These findings are clinically important because there are currently no medications approved specifically for cocaine use disorder.
They also require caution. The trial was small, conducted at a single research center, and paired psilocybin with an extensive course of psychotherapy. Participants were highly motivated, medically screened, and required to abstain from cocaine for seven days before the dosing session.
The study tested a complete treatment protocol under controlled conditions. It did not test psilocybin alone or unsupervised use.
What the Study Actually Tested
Researchers at the University of Alabama at Birmingham conducted a randomized, quadruple-blind, active-placebo-controlled trial.
Participants, therapists, outcome assessors, and independent statisticians were intended to remain unaware of treatment assignment.
The researchers assigned 20 participants to receive psilocybin at a dose of 25 milligrams per 70 kilograms of body weight. The median dose administered in this group was 32 milligrams, with individual doses adjusted for body weight.
The remaining 20 participants received 100 milligrams of diphenhydramine, an antihistamine that can cause noticeable physical and psychological effects. It was selected as an active placebo to make treatment assignment more difficult to identify than it would have been with an inert capsule.
Both groups received the same manualized psychotherapy.
Before the dosing session, participants completed four or five preparation sessions lasting approximately two hours each. After dosing, they were offered five weekly integration sessions lasting approximately one hour each.
The psychotherapy combined a client-centered approach with cognitive behavioral treatment for cocaine use disorder.
Participants were then assessed 90 and 180 days after completing treatment.
This means the intervention involved considerably more than administering psilocybin. It included screening, preparation, behavioral treatment, an all-day supervised session, integration, drug-use monitoring, and extended follow-up.
Participants Were Motivated and Carefully Selected
The researchers recruited adults aged 25 and older who met diagnostic criteria for cocaine dependence, reported using cocaine on at least four days during the previous month, and expressed a goal of complete abstinence.
Participants also needed to be in sufficiently good general health and have no recent history of hallucinogen use.
The study excluded people with several conditions that are common in real-world addiction treatment. Exclusion criteria included current psychiatric disorders other than substance use or nicotine dependence, uncontrolled hypertension, the use of certain psychiatric medications, and a personal or family history of psychotic or bipolar disorders.
Participants were also required to complete seven days of cocaine abstinence before the dosing session, confirmed through urine testing.
That requirement supported medical safety by reducing the risk of combining recent cocaine exposure with the cardiovascular and psychological effects of psilocybin.
It also selected for people who could achieve at least a brief period of abstinence before receiving the experimental treatment.
The trial therefore did not represent everyone living with cocaine use disorder. It examined a motivated and carefully screened subgroup able to participate in an intensive research protocol.
The Sample Was More Representative Than Most Psychedelic Trials
One of the study’s most important strengths was the population it enrolled.
Of the 40 participants, 33 were Black and seven were white. Their median age was 50, and 33 were men.
Twenty-six participants, representing 65 percent of the sample, reported an annual individual income of $20,000 or less. Four were experiencing homelessness, and two lived in a halfway house or therapeutic community.
Most psychedelic clinical trials have enrolled participants who are disproportionately white, financially secure, highly educated, and already interested in psychedelics.
This study reached a population more closely resembling many communities disproportionately affected by cocaine use disorder and its criminal, economic, and health consequences.
Only three participants had ever used a psychedelic before, and none reported psychedelic use during the previous three years.
This distinction improves the study’s relevance and may have affected expectancy and blinding. Participants with extensive psychedelic experience are more likely to recognize whether they received an active psychedelic, potentially influencing their expectations and outcome reports.
The trial shows that rigorous psychedelic research can include historically underrepresented and socioeconomically disadvantaged participants.
It also demonstrates that representative recruitment depends on community relationships, trust, accessible study procedures, and a willingness to work with people who may face transportation, housing, communication, or scheduling barriers.
Psilocybin Was Associated With More Abstinent Days
The researchers measured the percentage of days on which participants did not use cocaine.
Drug use was assessed through timeline followback interviews, a structured method that asks participants to reconstruct their daily substance use over a defined period. Urine testing was used to confirm reports of abstinence during study visits.
Participants who received psilocybin had a significantly higher percentage of cocaine-abstinent days than those who received diphenhydramine.
The reported difference was approximately 29 percentage points after accounting for the study’s repeated measurements and time periods.
The researchers also examined complete abstinence, defined as no cocaine use from the post-dose integration period through the 180-day follow-up.
Six of the 20 psilocybin participants, or 30 percent, met this standard. None of the 20 active-placebo participants did.
This produced an estimated odds ratio of 18.37 in favor of psilocybin.
That number sounds dramatic, but it should be interpreted carefully. Because there were only 40 participants and no one in the placebo group achieved complete abstinence, the confidence interval was extremely wide.
The result indicates a meaningful signal. It does not provide a precise estimate of how much more likely abstinence would be in a larger population.
The Risk of Cocaine Lapse Was Lower
The study also measured the time between the dosing session and a participant’s first reported use of cocaine.
Participants in the psilocybin group had a lower risk of lapse over time than those in the active-placebo group.
The reported hazard ratio was 0.28. This corresponds to an estimated 72 percent lower risk of lapse during the study period.
At 90 days, the estimated probability of remaining free from cocaine lapse was 55 percent in the psilocybin group and approximately 21 percent in the placebo group.
This result may be particularly important because substance use recovery is rarely captured by a single outcome.
Complete abstinence is one meaningful standard, but reductions in frequency, longer periods before relapse, and quicker recovery after a lapse may also improve health and functioning.
The study found signals across several related outcomes rather than relying on only one measure.
Still, a lower risk of lapse in 20 participants must be replicated before it can guide routine clinical care.
Blinding Worked Better for Participants Than for Therapists
Functional unblinding is a persistent challenge in psychedelic research.
Psilocybin produces noticeable changes in perception, emotion, cognition, and consciousness. Participants and clinicians can often infer whether an active psychedelic was administered, even when a study is formally blinded.
This knowledge may influence expectations, clinical interactions, and self-reported outcomes.
The cocaine use disorder trial attempted to address this by using diphenhydramine as an active placebo and measuring treatment guesses and expectations.
Approximately half of the placebo participants correctly identified their assignment, which is close to chance. Two participants who received psilocybin believed they had received placebo.
This suggests that participant blinding performed better than it has in many psychedelic trials.
Therapist blinding was much less successful. Therapists correctly guessed the treatment assignment for 39 of the 40 participants.
The consequences are uncertain. Therapists may have behaved differently based on what they believed a participant received, even while following a manualized protocol.
The study also found that expectations remained high in both groups, although participants receiving psilocybin reported somewhat higher expectations after dosing.
The outcomes cannot therefore be reduced entirely to expectancy or unblinding. Neither can those influences be ruled out.
Psychotherapy Was a Major Part of the Protocol
Both study groups received approximately one month of psychotherapy before dosing and another month afterward.
The preparation sessions were longer and more numerous than those used in many psychedelic trials. Participants could receive a fifth preparation session if they needed additional support with adherence or readiness.
The psychotherapy addressed cocaine use through cognitive behavioral strategies while also preparing participants for an intense altered state.
After dosing, integration sessions helped participants discuss the experience, relate it to their goals, and continue working toward abstinence.
Every participant in the psilocybin group completed the integration process, compared with 15 of the 20 participants receiving placebo.
This raises several possible interpretations.
Psilocybin may have increased motivation to remain engaged with treatment. The subjective experience may have made integration feel more useful. Participants in the placebo group may have been less engaged because their experience did not meet expectations.
The additional treatment exposure could also have influenced outcomes. Psilocybin participants spent more time in integration on average, making it difficult to separate the effects of the drug from continued therapeutic engagement.
The study did not include a psilocybin-only group or a group receiving psychotherapy without a drug session.
It therefore cannot tell us whether psilocybin would produce similar outcomes with less psychological support or whether the psychotherapy protocol was necessary for the observed benefit.
Why Psilocybin Might Influence Addictive Behavior
The trial was designed to test outcomes, not prove a mechanism.
Still, several hypotheses may help explain why a psychedelic experience could influence substance use.
Psilocybin may temporarily increase psychological flexibility, allowing a person to examine established habits, emotional responses, and beliefs from a different perspective.
Participants may experience insights about how cocaine use conflicts with their values, relationships, health, or long-term goals.
The experience may also reduce ambivalence. Many people seeking addiction treatment simultaneously want to stop using and remain attached to the relief, stimulation, identity, or social connections associated with the drug.
A psychologically intense experience could strengthen commitment to change by making the consequences of continued use feel more immediate or personally significant.
Changes in mood, self-compassion, motivation, and perceived meaning may also contribute.
These explanations remain hypotheses. The study did not demonstrate that mystical experiences, insight, brain plasticity, or any other specific process caused abstinence.
A striking experience is not automatically therapeutic, and a person does not need a mystical experience to benefit.
Future studies will need to examine which psychological and biological changes predict abstinence and which merely accompany psilocybin intoxication.
Safety Findings Were Reassuring but Preliminary
No serious treatment-related adverse events occurred during the trial.
Adverse events were reported or observed in 13 of the 20 psilocybin participants and two of the 20 placebo participants. Most occurred during the all-day session and resolved without lasting consequences.
Temporary increases in blood pressure occurred in six psilocybin participants. Five experienced emotional distress, and five cried during the session. Three later reported headaches.
Other reported events included vomiting, agitation, altered perception, heightened visual imagery, and one temporary episode of tachycardia.
One participant reported passive suicidal ideation after experiencing a cocaine lapse. Investigators determined that the event was not related to the intervention, and it resolved without further consequences.
The absence of serious treatment-related events is encouraging, but the sample was too small to identify uncommon complications.
Participants were also carefully screened, required to stop using cocaine before dosing, and monitored in a clinical research environment.
The findings should not be used to imply that psilocybin is safe for people to use independently while actively using cocaine or other substances.
Combining stimulant exposure, cardiovascular vulnerability, psychiatric instability, and an intense psychedelic state may create risks not represented in this trial.
The Study Has Important Limitations
The most obvious limitation is the sample size.
With only 20 participants in each group, a small number of outcomes can substantially change the results. The wide confidence interval around complete abstinence reflects this uncertainty.
The study was also conducted at a single center, with one lead researcher serving as the primary therapist. The authors acknowledged that this could introduce allegiance bias, although they attempted to reduce variability through a manualized psychotherapy protocol.
Cocaine use was partly self-reported. Urine testing supported verification, but urine samples detect use only within a limited window and cannot confirm every reported abstinent day.
The researchers did not conduct a formal sample-size calculation before beginning the study. They also tested multiple primary outcomes without applying a statistical correction for multiple comparisons.
Recruitment and data collection took approximately nine years because of limited funding, the political environment surrounding psychedelic research, recruitment challenges, and the COVID-19 pandemic.
Treatment also required substantial time and participation. Of 910 people assessed for eligibility, 186 consented, 74 qualified, and 40 were randomized.
This illustrates how different a controlled efficacy trial may be from routine addiction care.
People facing unstable housing, legal involvement, medical complications, psychiatric comorbidity, transportation barriers, or immediate financial pressures may have difficulty completing this level of preparation and follow-up.
What This Means for Addiction Treatment
The study does not justify replacing established addiction services with psilocybin.
Cocaine use disorder is a complex condition influenced by neurobiology, trauma, housing, poverty, social environment, mental health, criminalization, and access to care.
No single drug session can address every factor sustaining cocaine use.
The findings do suggest that psilocybin-assisted treatment deserves larger trials, particularly because there is no approved medication specifically for cocaine use disorder.
Future studies should compare different doses, levels of psychotherapy, retreatment strategies, and community-based delivery models. They should also include participants with common psychiatric and medical conditions that were excluded from this initial trial.
Researchers will need to determine whether psilocybin improves outcomes when combined with contingency management, peer recovery services, medications targeting co-occurring conditions, or other evidence-based interventions.
Cost and accessibility will also matter.
A protocol involving up to ten psychotherapy sessions, medical screening, an all-day administration session, and six months of follow-up may be difficult to deliver at scale.
Streamlining the model should not come at the expense of safety, but unnecessary requirements could make a promising intervention inaccessible to the populations most affected by cocaine use disorder.
What Practitioners and Training Programs Should Take From the Study
The study reinforces that addiction-focused psychedelic care requires specialized competence.
Facilitators and clinicians must understand substance use patterns, withdrawal, intoxication, relapse, overdose risk, motivation, trauma, and co-occurring mental health conditions.
Screening should examine recent stimulant use, cardiovascular health, medications, suicidality, psychosis, bipolar-spectrum symptoms, housing stability, and available support.
A period of verified cocaine abstinence was required before dosing in this trial. Any future clinical model would need clear standards for recent use and medical stability.
Practitioners must also avoid treating a lapse as proof that treatment failed. Addiction is often chronic and relapsing. A participant may reduce use, remain abstinent for months, lapse once, and still show meaningful improvement.
Follow-up plans should address both abstinence and harm reduction. They should include pathways for additional treatment, crisis support, overdose prevention, and coordination with licensed addiction professionals.
Scope of practice remains essential. Psychedelic facilitation does not automatically qualify someone to diagnose or treat cocaine use disorder.
A Strong First Signal That Needs a Larger Test
This study provides the first randomized evidence that psilocybin combined with psychotherapy may improve cocaine-use outcomes.
Participants receiving psilocybin reported more abstinent days, a longer time before lapse, and a higher likelihood of complete abstinence through six months.
The trial also demonstrated that psychedelic research can successfully recruit and retain participants from Black and lower-income communities that have often been underrepresented in the field.
That achievement matters scientifically and ethically.
The results are not yet enough to establish a treatment standard.
Forty participants at one research center cannot show how the intervention will perform across different regions, cultures, clinical settings, or levels of addiction severity. The psychotherapy was intensive, the eligibility criteria were selective, and therapists could almost always identify who received psilocybin.
The next step is replication through larger, multisite trials that preserve representative recruitment while testing practical models of care.
If those studies confirm the signal, psilocybin could become an important option for a condition that currently has no approved medication.
For now, the study offers something more measured but still valuable: evidence strong enough to justify moving forward, and limitations clear enough to show how carefully the field must proceed.
Sources
JAMA Network Open: Psilocybin in the Treatment of Cocaine Use Disorder
Psychedelic Alpha: Psilocybin for Cocaine Use Disorder, a Trial Ten Years in the Making
ClinicalTrials.gov Record: Psilocybin-Facilitated Treatment for Cocaine Use
JAMA Network Open Supplemental Trial Protocol and Statistical Analysis Plan